Macrophage derived growth factors modulate Fas ligand expression in cultured endometrial stromal cells: a role in endometriosis

被引:97
作者
Garcia-Velasco, JA [1 ]
Arici, A [1 ]
Zreik, T [1 ]
Naftolin, F [1 ]
Mor, G [1 ]
机构
[1] Yale Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol, New Haven, CT 06520 USA
关键词
bFGF; Fas-FasL system; immunoprivilege; PDGF; TGF-beta(1);
D O I
10.1093/molehr/5.7.642
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Fas-Fas ligand (Fast) interactions play a significant role in the immune privilege status of cel-tain cell populations, and several cytokines and growth factors can modulate their expression. When a Fast-expressing cell binds a Fas-bearing immune cell, it triggers its death by apoptosis. In this study, we demonstrate that normal human endometrial epithelial but not stromal cells express Fast. Moreover, we showed that macrophage-conditioned media induced Fast expression by endometrial stromal cells in a dose-dependent manner. To elucidate which macrophage product was responsible for the up-regulation of Fast, endometrial stromal cell cultures were treated with the macrophage products platelet-derived growth factor (PDGF), transforming growth factor (TGF)-beta(1) and basic fibroblast growth factor (bFGF). The first two (which are known to be elevated in the peritoneal; fluid of women with endometriosis) induced a dose-dependent upregulation of Fast expression, which was specifically inhibited by the antibody. Interestingly, bFGF (which is not elevated in peritoneal fluid of women with endometriosis) did not induce any response. These results suggest that the pro-inflammatory nature of the peritoneal fluid of women with endometriosis induces the Fast expression by regurgitated endometrial cells, and signals Fas-mediated cell death of activated immune cells. This could be a mechanism for endometrial cells to escape immune surveillance, implant and grow.
引用
收藏
页码:642 / 650
页数:9
相关论文
共 52 条
  • [1] Interleukin-8 induces proliferation of endometrial stromal cells: a potential autocrine growth factor
    Arici, A
    Seli, E
    Zeyneloglu, HB
    Senturk, LM
    Oral, E
    Olive, DL
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (04) : 1201 - 1205
  • [2] Ashley DM, 1998, CANCER RES, V58, P302
  • [3] BARTOSIK D, 1986, FERTIL STERIL, V46, P796
  • [4] Bechmann I, 1998, EUR J NEUROSCI, V10, P165
  • [5] A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION
    BELLGRAU, D
    GOLD, D
    SELAWRY, H
    MOORE, J
    FRANZUSOFF, A
    DUKE, RC
    [J]. NATURE, 1995, 377 (6550) : 630 - 632
  • [6] PLATELET-DERIVED GROWTH-FACTOR (PDGF), EPIDERMAL GROWTH-FACTOR (EGF), AND EGF AND PDGF BETA-RECEPTORS IN HUMAN ENDOMETRIAL TISSUE - LOCALIZATION AND INVITRO ACTION
    CHEGINI, N
    ROSSI, MJ
    MASTERSON, BJ
    [J]. ENDOCRINOLOGY, 1992, 130 (04) : 2373 - 2385
  • [7] CHEGINI N, 1994, OBSTET GYNECOL, V83, P455
  • [8] Interferon-gamma-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells
    Dao, T
    Ohashi, K
    Kayano, T
    Kurimoto, M
    Okamura, H
    [J]. CELLULAR IMMUNOLOGY, 1996, 173 (02) : 230 - 235
  • [9] The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection
    Dockrell, DH
    Badley, AD
    Villacian, JS
    Heppelmann, CJ
    Algeciras, A
    Ziesmer, S
    Yagita, H
    Lynch, DH
    Roche, PC
    Leibson, PJ
    Paya, CV
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) : 2394 - 2405
  • [10] Gaetje R, 1997, AM J PATHOL, V150, P461